Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa malaria sporozoite challenge study of ChAd63/MVA combination vaccine regimens
2012-004416-66Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Nov 2012
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ChAd63 ME-TRAP, ChAd63 CS, MVA ME-TRAP, MVA-CS, adch63 ama1 and 1 more in Falciparum malaria (PF) (3 arms), sponsored by University of Oxford. Primary endpoints: Efficacy of Group 1 vaccination regimen and Efficacy of Group 2 vaccination regimen. Started Nov 2012; status: completed.
02
Drugs
ChAd63 ME-TRAPChAd63 CSMVA ME-TRAPMVA-CSadch63 ama1
03
Conditions
Falciparum malaria (PF)
Beyond the preview
Go deeper on 2012-004416-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004416-66.